Fibroblast growth factor-23 (FGF-23) is associated with an elevated risk of death and of cardiovascular (CV) events in patients with chronic kidney disease (CKD), according to findings published in the Journal of the American Society of Nephrology (2011;22:1913-1922).

In a study of 1,099 stored plasma samples from patients with advanced CKD, researchers observed that, compared with patients in the lowest FGF-23 quartile, each subsequent quartile was associated with a progressively higher death risk.

The two highest quartiles were associated with an elevated risk for CV events and initiation of dialysis.

Continue Reading